Members will help to guide the development strategy of existing pipeline as well as identify innovative applications for the cytoDRiVE™ platform
Feb. 5, 2020, 08:00 AM Eastern Standard Time
CAMBRIDGE, Mass., Feb. 5, 2020 – Obsidian Therapeutics, a biotechnology company pioneering controllable cell and gene therapies, announced the formation of its Scientific Advisory Board (SAB). Obsidian’s SAB is comprised of distinguished research scientists, professors and industry experts recognized as key opinion leaders in the fields of immuno-oncology, synthetic biology, and cell and gene therapy.
“Obsidian is privileged to have this group of prestigious, multidisciplinary advisors dedicated to advancing the research and development of cytoDRiVE™,” said Paul K. Wotton, Ph.D., Obsidian’s Chief Executive Officer. “Their scientific perspectives will provide the utmost value in supporting the advancement of Obsidian’s pipeline into the clinic to improve outcomes for patients. Our management team is eager to leverage their expertise to optimize our preclinical R&D activities. Additionally, by utilizing the expertise of all the members – including adoptive T cell immunobiology, cell therapy, protein synthesis and control, and gene delivery – we will be able to continue to identify new applications for our platform.”
The members of Obsidian’s Scientific Advisory Board are as follows:
About Obsidian Therapeutics
Obsidian Therapeutics is a biotechnology company pioneering controllable cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian’s proprietary cytoDRiVE™ technology provides a way to control protein degradation using FDA-approved small molecules, permitting precise control of the timing and level of protein expression. The cytoDRiVE™ platform can be applied to design controllable intracellular, membrane and secreted proteins for cell and gene therapies as well as other applications. The Company’s initial applications focus on developing novel cell therapies for the treatment of cancer. Obsidian is headquartered in Cambridge, Mass. For more information, please visit www.obsidiantx.com.
Russo Partners, LLC